Medopa (Dopamine Hydrochloride)

Dopamine hydrochloride acts on dopamine D1 receptors at low doses, causing vasodilation, while moderate doses stimulate β1‑adrenergic receptors to increase heart contractility and rate. At higher doses it also activates α‑adrenergic receptors, leading to vasoconstriction. This dose‑dependent profile allows clinicians to tailor vascular and cardiac effects.

The dose of Medopa is individualized by the prescribing clinician based on the patient’s hemodynamic status, underlying condition, and response to therapy. Dosing is typically started at a low infusion rate and titrated upward to achieve target blood pressure or cardiac output, following established clinical guidelines.

Safety data for dopamine hydrochloride in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with obstetric specialists.

To order Medopa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Both dopamine and norepinephrine are vasoactive agents, but dopamine offers dose‑dependent renal vasodilation at low doses and combined inotropic and vasoconstrictive effects at higher doses. Norepinephrine primarily provides potent α‑adrenergic vasoconstriction with modest β1 activity, making it more suitable for pure vasoconstriction without the renal benefits of low‑dose dopamine.

Medopa must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before administration, the solution should be inspected for particulate matter and used within the time frame recommended by the manufacturer after dilution.

Medopa is given as an intravenous infusion. The sterile solution is typically diluted in compatible IV fluids and infused through a calibrated infusion set. The rate is adjusted according to the patient’s blood pressure, heart rate, and clinical response, with continuous hemodynamic monitoring.

Serious risks include myocardial ischemia or infarction, severe arrhythmias such as ventricular tachycardia, tissue necrosis from extravasation at the infusion site, and hypertensive crisis when high doses cause excessive α‑adrenergic vasoconstriction. Immediate medical attention is required if any of these events occur.

Medopa is contraindicated in patients with known hypersensitivity to dopamine or any component of the formulation. Caution is advised in individuals with uncontrolled hypertension, recent myocardial infarction, or severe peripheral vascular disease, as the drug’s vasoconstrictive properties may exacerbate these conditions.